# Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

> **NCT00786383** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** IMC-1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B

## Key facts

- **NCT ID:** NCT00786383
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00786383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00786383, "Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00786383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*